Kintegral Advisory LLC Reduces Holdings in Agilent Technologies, Inc. (NYSE:A)

Kintegral Advisory LLC lowered its position in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) by 32.9% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,569 shares of the medical research company's stock after selling 5,674 shares during the quarter. Kintegral Advisory LLC's holdings in Agilent Technologies were worth $1,353,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Wellington Management Group LLP grew its stake in Agilent Technologies by 0.6% during the 4th quarter. Wellington Management Group LLP now owns 9,306,805 shares of the medical research company's stock valued at $1,250,276,000 after acquiring an additional 59,781 shares in the last quarter. Geode Capital Management LLC increased its stake in Agilent Technologies by 0.8% in the 4th quarter. Geode Capital Management LLC now owns 7,002,671 shares of the medical research company's stock valued at $938,291,000 after buying an additional 53,992 shares during the period. Pictet Asset Management Holding SA lifted its position in Agilent Technologies by 0.9% in the 4th quarter. Pictet Asset Management Holding SA now owns 5,213,739 shares of the medical research company's stock worth $700,414,000 after buying an additional 47,495 shares in the last quarter. Deutsche Bank AG boosted its stake in shares of Agilent Technologies by 0.9% during the 4th quarter. Deutsche Bank AG now owns 4,436,700 shares of the medical research company's stock valued at $596,026,000 after buying an additional 38,348 shares during the period. Finally, Northern Trust Corp grew its holdings in shares of Agilent Technologies by 12.3% during the 4th quarter. Northern Trust Corp now owns 4,192,790 shares of the medical research company's stock valued at $563,259,000 after acquiring an additional 457,713 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. JPMorgan Chase & Co. lowered their price objective on Agilent Technologies from $160.00 to $155.00 and set an "overweight" rating on the stock in a report on Thursday, May 29th. Barclays lifted their price target on shares of Agilent Technologies from $115.00 to $125.00 and gave the company an "equal weight" rating in a research report on Tuesday, June 24th. TD Cowen raised their target price on shares of Agilent Technologies to $150.00 and gave the company a "buy" rating in a research note on Thursday, May 29th. Wells Fargo & Company decreased their price target on shares of Agilent Technologies from $155.00 to $135.00 and set an "overweight" rating for the company in a report on Thursday, April 17th. Finally, Robert W. Baird dropped their price objective on Agilent Technologies from $159.00 to $140.00 and set an "outperform" rating on the stock in a research note on Thursday, May 22nd. Six investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, Agilent Technologies currently has an average rating of "Moderate Buy" and a consensus target price of $140.92.

Agilent Technologies Trading Up 0.4%

NYSE A traded up $0.50 during trading hours on Friday, reaching $121.16. The company's stock had a trading volume of 944,958 shares, compared to its average volume of 1,844,497. The firm has a fifty day simple moving average of $113.79 and a 200-day simple moving average of $123.27. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.09 and a quick ratio of 1.60. Agilent Technologies, Inc. has a 52 week low of $96.43 and a 52 week high of $153.84. The stock has a market cap of $34.42 billion, a P/E ratio of 29.91, a P/E/G ratio of 3.68 and a beta of 1.23.

Agilent Technologies (NYSE:A - Get Free Report) last issued its quarterly earnings results on Wednesday, May 28th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.26 by $0.05. Agilent Technologies had a return on equity of 25.92% and a net margin of 17.59%. The firm had revenue of $1.67 billion for the quarter, compared to analyst estimates of $1.63 billion. During the same period in the previous year, the firm earned $1.22 earnings per share. The company's revenue was up 6.0% compared to the same quarter last year. Equities analysts forecast that Agilent Technologies, Inc. will post 5.58 earnings per share for the current fiscal year.

Agilent Technologies Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 23rd. Shareholders of record on Tuesday, July 1st will be paid a $0.248 dividend. The ex-dividend date of this dividend is Tuesday, July 1st. This represents a $0.99 annualized dividend and a yield of 0.82%. Agilent Technologies's dividend payout ratio (DPR) is 24.44%.

Insider Activity at Agilent Technologies

In other news, CEO Padraig Mcdonnell sold 1,508 shares of the firm's stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $117.44, for a total transaction of $177,099.52. Following the completion of the sale, the chief executive officer owned 37,448 shares in the company, valued at $4,397,893.12. This trade represents a 3.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.